Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 2
2008 1
2009 1
2010 2
2011 2
2013 3
2014 1
2015 1
2016 3
2017 3
2018 1
2019 8
2020 5
2021 4
2022 6
2023 8
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

51 results

Results by year

Filters applied: . Clear all
Page 1
Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
Guillo L, Abreu M, Panaccione R, Sandborn WJ, Azevedo VF, Gensler L, Moghaddam B, Ahuja V, Ali SA, Allez M, Ananthakrishnan AN, Bhattacharya A, Dubinsky M, Griffiths A, Hart A, Korelitz B, Kotze PG, Koutroubakis IE, Lakatos PL, Lindsay JO, Magro F, Mantzaris GJ, Ng SC, O'Morain C, Panés J, Parigi T, Ran Z, Rogler G, Rubin DT, Sachar DB, Siegmund B, Steinwurz F, Tysk C, Vavricka S, Verstraete SG, Brezin AP, Haemel AK, Dignass A, Sands BE, Danese S, Peyrin-Biroulet L. Guillo L, et al. Among authors: haemel ak. Lancet Gastroenterol Hepatol. 2022 Mar;7(3):254-261. doi: 10.1016/S2468-1253(21)00297-1. Epub 2022 Jan 17. Lancet Gastroenterol Hepatol. 2022. PMID: 35051383
A national survey comparing practice patterns and residency training satisfaction for categorical dermatology versus combined internal medicine and dermatology trained physicians.
Han J, Ronkainen SD, Jacobsen A, Bohjanen KA, Merola JF, Colavincenzo ML, DeWitt CA, Fett NM, Haemel A, Rosenbach M, Werth VP, Lunos S, Goldfarb N. Han J, et al. Among authors: haemel a. Dermatol Online J. 2023 Jun 15;29(3). doi: 10.5070/D329361425. Dermatol Online J. 2023. PMID: 37591265
Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis.
Ferdowsi N, Huq M, Stevens W, Hudson M, Wang M, Tay T, Burchell JL, Mancuso S, Rabusa C, Sundararajan V, Prior D, Proudman SM, Baron M, Nikpour M; Scleroderma Clinical Trials Consortium Damage Index Working Group, The Australian Scleroderma Interest Group, Canadian Scleroderma Research Group; Scleroderma Clinical Trials Consortium Damage Index Working Group, TheAustralian Scleroderma Interest Group, Canadian Scleroderma Research Group. Ferdowsi N, et al. Ann Rheum Dis. 2019 Jun;78(6):807-816. doi: 10.1136/annrheumdis-2018-214764. Epub 2019 Mar 30. Ann Rheum Dis. 2019. PMID: 30928903
Rosai-Dorfman as a clinical mimicker of relapsing polychondritis.
Song E, Pincus L, Berger A, Butrymowicz A, Haemel A. Song E, et al. Among authors: haemel a. JAAD Case Rep. 2020 Sep 15;6(12):1221-1223. doi: 10.1016/j.jdcr.2020.09.004. eCollection 2020 Dec. JAAD Case Rep. 2020. PMID: 33294547 Free PMC article. No abstract available.
Telangiectases in Systemic Sclerosis.
Jacobson R, Agnihothri R, Haemel A. Jacobson R, et al. Among authors: haemel a. JAMA Dermatol. 2021 Apr 1;157(4):457. doi: 10.1001/jamadermatol.2020.4831. JAMA Dermatol. 2021. PMID: 33595597 No abstract available.
51 results